# OMER earnings call intelligence

LOPJLB CallCard / temporal rollup · freemium · [stock page](https://www.lopjlb.com/stock/OMER) · [Earnings tab](https://www.lopjlb.com/stock/OMER?tab=earnings)

Updated: 2026-11-16T07:07:33

Quarters analyzed: 8

## Cross-quarter narrative

Across the series of Omeros CallCards the company moved from a cash‑rich but loss‑making position in late 2024 toward a cash‑flow‑positive, product‑launching business by mid‑2026. Early calls emphasized a pending resubmission of the narsoplimab BLA and the start of Phase‑3 enrollment for zaltenibart, while the balance sheet was bolstered through debt restructuring. By Q1 2025 the firm paused non‑core programs, highlighted capital constraints, and listed multiple regulatory and reimbursement fears. Subsequent quarters saw the narsoplimab PDUFA date pushed back, continued debt extensions, and growing physician enthusiasm, yet the zaltenibart Phase‑3 trial remained on hold. A turning point arrived in Q4 2025 with FDA approval of YARTEMLEA and a $240 million asset sale to Novo Nordisk, delivering upfront cash that retired debt and funded a strong launch that generated $11.1 million in Q1 2026 and $32.2 million in Q2 2026. While regulatory uncertainties linger for the EMA filing and the PDE7 program, the company now reports positive cash flow, high per‑vial pricing, and expanding market uptake, marking a clear shift from earlier financial strain and program pauses to a more stable, revenue‑generating trajectory.

## Latest CallCard · Q2

Omeros reports strong Yartemlia launch with $32.2M gross sales in first full quarter, positive cash flow, share/note repurchases reducing dilution; EU reexamination underway, pipeline advancing across MASP-2, PDE7, TCAT, oncology.','tone': {'mgmt': 0.7, 'mgmt_rationale': 'Management highlights stron

**Guidance:** vague

**Tone:** mgmt 0 · Q&A pressure 0 · divergence 0

## Quarter one-liners

- **2026 Q2:** Omeros reports strong Yartemlia launch with $32.2M gross sales in first full quarter, positive cash flow, share/note repurchases reducing dilution; EU reexamination underway, pipeline advancing across MASP-2, PDE7, TCAT, oncology.','tone': {'mgmt': 0.7, 'mgmt_rationale': 'Management highlights stron
- **2026 Q1:** Omeros launched YARTEMLEA for TA-TMA in Jan 2026 with $11.1M gross revenue in Q1, strong early adoption (30 accounts, accelerated P&T approvals), cash flow positive, pipeline advancing across complement, addiction, antimicrobial and oncology programs. Novo deal provided $240M upfront. No revenue gui
- **2025 Q4:** Omeros reported a turning point in Q4 2025 with FDA approval of YARTEMLEA, a $240 million zaltenibart sale to Novo Nordisk and early launch momentum, while flagging regulatory and milestone uncertainties ahead of 2027 cash‑flow positivity.
- **2025 Q3:** —
- **2025 Q2:** Omeros reports Q2 loss narrowing, debt restructuring extends maturities, narsoplimab PDUFA extended to Dec 26, potential multibillion-dollar asset deal discussed, Zaltenibart Phase III paused. Cash $28.7M plus $20.6M July offering. Q3 expenses guided lower. Physician enthusiasm high for narsoplimab 
- **2025 Q1:** OMER reported a $33.5M Q1 loss, strengthened its balance sheet via a debt exchange, and focused on advancing narsoplimab toward an FDA decision by Sep 25 while pausing non‑core programs to conserve cash.
- **2024 Q4:** Omeros resubmitted narsoplimab BLA for TA-TMA with PDUFA Sept 2025, advancing zaltenibart Phase 3 in PNH, restructuring debt and seeking partnerships to fund operations.','tone': {'mgmt': 0.3, 'mgmt_rationale': 'Management highlights strong narsoplimab survival data, PDUFA date set, launch preparati
- **2024 Q3:** Omeros reports Q3 net loss of $32.2M, cash $123.2M; narsoplimab BLA resubmission imminent pending FDA reply on statistical plan; zaltenibart Phase 3 PNH program underway with enrollment expected early 2025, C3G Phase 3 planned H1 2025; OMIDRIA HOPD payment starts Jan 2025.','tone':{'mgmt':0.6,'mgmt_

## Theme arcs

- **Financial health** (improving): Debt restructuring, asset sale, and positive cash flow replace earlier cash burn and financing concerns
- **Regulatory progress** (improving): Narsoplimab pending decision, YARTEMLEA FDA approval and launch, though EMA and PDE7 remain pending
- **Market demand** (improving): Strong early YARTEMLEA uptake, P&T approvals at top transplant centers, expanding payer coverage
- **Capital strategy** (improving): Debt exchange, extended maturities, and $240 M upfront from Novo improve liquidity and fund launch

## Guidance path

2024 Q3:vague → 2024 Q4:vague → 2025 Q1:maintained → 2025 Q2:vague → 2025 Q3:vague → 2025 Q4:vague → 2026 Q1:vague → 2026 Q2:vague

---

Research context only. Not personalized investment advice.

API: `GET /bff/api/bigfive/earnings-intel/OMER`
